Your browser doesn't support javascript.
loading
Prevalence of hypersensitivity reactions in various forms of mastocytosis: A pilot study of 2485 adult patients with mastocytosis collected in the ECNM registry.
Niedoszytko, Marek; Gorska, Aleksandra; Brockow, Knut; Bonadonna, Patrizia; Lange, Magdalena; Kluin-Nelemans, Hanneke; Oude-Elberink, Hanneke; Sabato, Vito; Shoumariyeh, Khalid; von Bubnoff, Dagmar; Müller, Sabine; Illerhaus, Anja; Doubek, Michael; Angelova-Fischer, Irena; Hermine, Olivier; Arock, Michel; Elena, Chiara; Malcovati, Luca; Yavuz, Akif Selim; Schug, Tanja Daniela; Fortina, Anna Belloni; Judit, Várkonyi; Gotlib, Jason; Panse, Jens; Vucinic, Vladan; Reiter, Andreas; Schwaab, Juliana; Triggiani, Massimo; Mattsson, Mattias; Breynaert, Christine; Romantowski, Jan; Zanotti, Roberta; Olivieri, Elisa; Zink, Alexander; van de Ven, Annick; Stefan, Alex; Barete, Stephane; Caroppo, Francesca; Perkins, Cecelia; Kennedy, Vanessa; Christen, Deborah; Jawhar, Mohamad; Luebke, Johannes; Parente, Roberta; Levedahl, Kerstin; Hadzijusufovic, Emir; Hartmann, Karin; Nedoszytko, Boguslaw; Sperr, Wolfgang R; Valent, Peter.
Affiliation
  • Niedoszytko M; Department of Allergology, Medical University of Gdansk, Gdansk, Poland.
  • Gorska A; Department of Allergology, Medical University of Gdansk, Gdansk, Poland.
  • Brockow K; Department of Dermatology and Allergy Biederstein, Technical University of Munich, School of Medicine, Munich, Germany.
  • Bonadonna P; Allergy Unit, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy.
  • Lange M; Department of Dermatology, Venereology and Allergology, Medical University of Gdansk, Gdansk, Poland.
  • Kluin-Nelemans H; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Oude-Elberink H; Department of Allergology, University Medical Center, Groningen, The Netherlands.
  • Sabato V; Department of Immunology, Allergology Rheumatology University of Antwerp and Antwerp University Hospital, Edegem, Belgium.
  • Shoumariyeh K; Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany and German Cancer Consortium (DKTK), Partner Site Freiburg, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • von Bubnoff D; Dagmar von Bubnoff, Department of Dermatology, Allergy and Venerology, University of Schleswig Holstein, Lübeck, Germany.
  • Müller S; Department of Dermatology, Medical Centre-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Illerhaus A; Dermatologie, Uniklinik Köln, Köln, Germany.
  • Doubek M; Brno University Hospital, Brno, Czech Republic.
  • Angelova-Fischer I; Department of Dermatology, Kepler University Hospital, Linz, Austria.
  • Hermine O; Unit of Dermatology and CEREMAST, Pitié-Salpêtrière Hospital, Sorbonne Université, Paris, France.
  • Arock M; Department of Hematological Biology and CEREMAST, Pitié-Salpêtrière Hospital, Paris Sorbonne University, Paris, France.
  • Elena C; Department of Hematology, Fondazione IRCCS Fondazione Policlinico San Matteo, Pavia, Italy.
  • Malcovati L; Department of Hematology, Fondazione IRCCS Fondazione Policlinico San Matteo, Pavia, Italy.
  • Yavuz AS; Department of Molecular Medicine, University of Pavia, Pavia, Italy.
  • Schug TD; Istanbul University, Istanbul Faculty of Medicine, Istanbul, Türkiye.
  • Fortina AB; Medical University of Graz, Univ.Klinik für Dermatologie, Graz, Austria.
  • Judit V; Pediatric Dermatology, Internal Medicine, Azienda Ospedaliera, Università di Padova, Padova, Italy.
  • Gotlib J; Semmelweis University Budapest, Budapest, Hungary.
  • Panse J; Stanford University, School of Medicine, Hematology Clinic, Stanford, USA.
  • Vucinic V; Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Center for Integrated Oncology Aachen, Bonn Cologne, Duesseldorf (CIO ABCD), Aachen, Germany.
  • Reiter A; Universitätsklinikum Leipzig AöR, Leipzig, Germany.
  • Schwaab J; Universitätsmedizin Mannheim, III.Medizinische Klinik, Mannhein, Germany.
  • Triggiani M; Universitätsmedizin Mannheim, III.Medizinische Klinik, Mannhein, Germany.
  • Mattsson M; University of Salerno, Salerno, Italy.
  • Breynaert C; Uppsala University Hospital, Uppsala, Sweden.
  • Romantowski J; KU Leuven Department of Microbiology, Immunology and Transplantation, Allergy and Clinical Immunology ResearchGroup and MASTeL, University Hospitals Leuven, Leuven, Belgium.
  • Zanotti R; Department of Allergology, Medical University of Gdansk, Gdansk, Poland.
  • Olivieri E; Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.
  • Zink A; Allergy Unit, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy.
  • van de Ven A; Department of Dermatology and Allergy Biederstein, Technical University of Munich, School of Medicine, Munich, Germany.
  • Stefan A; Department of Allergology, University Medical Center, Groningen, The Netherlands.
  • Barete S; Clinic for Hematology and Oncology, Kepler University Hospital, Linz, Austria.
  • Caroppo F; Unit of Dermatology and CEREMAST, Pitié-Salpêtrière Hospital, Sorbonne Université, Paris, France.
  • Perkins C; Pediatric Dermatology, Internal Medicine, Azienda Ospedaliera, Università di Padova, Padova, Italy.
  • Kennedy V; Stanford University, School of Medicine, Hematology Clinic, Stanford, USA.
  • Christen D; Stanford University, School of Medicine, Hematology Clinic, Stanford, USA.
  • Jawhar M; Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Center for Integrated Oncology Aachen, Bonn Cologne, Duesseldorf (CIO ABCD), Aachen, Germany.
  • Luebke J; Universitätsmedizin Mannheim, III.Medizinische Klinik, Mannhein, Germany.
  • Parente R; Department of Hematology and Oncology, Helios Pforzheim, Pforzheim, Germany.
  • Levedahl K; Universitätsmedizin Mannheim, III.Medizinische Klinik, Mannhein, Germany.
  • Hadzijusufovic E; University of Salerno, Salerno, Italy.
  • Hartmann K; Uppsala University Hospital, Uppsala, Sweden.
  • Nedoszytko B; Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.
  • Sperr WR; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.
  • Valent P; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
Allergy ; 2024 Apr 23.
Article de En | MEDLINE | ID: mdl-38651829
ABSTRACT

BACKGROUND:

Hypersensitivity reactions (HR) are common in mastocytosis. However, little is known about triggers and risk factors. The registry of the European Competence Network on Mastocytosis (ECNM) enables reliable studies in a larger cohort of mastocytosis patients. We assessed prevalence, triggers and risk factors of HR in adults with mastocytosis in the ECNM registry.

METHODS:

Data were collected in 27 ECNM centers. We analyzed potential triggers (Hymenoptera venoms, food, drug, inhalant and others) and risk factors at diagnosis and during follow-up. The study group consisted of 2485 adults with mastocytosis, 1379 women (55.5%) and 1106 men (44.5%). Median age was 48.2 years (range 18-91 years).

RESULTS:

Nine hundred and forty eight patients (38.1%) reported one or more HR`. Most common triggers were Hymenoptera venoms in cutaneous mastocytosis (CM) and indolent systemic mastocytosis (ISM), whereas in advanced SM (advSM), most common elicitors were drugs, including nonsteroidal anti-inflammatory agents and penicillin. In multivariate analyses, tryptase level < 90 ng/mL, <15% infiltration by mast cells in bone marrow biopsy-sections, and diagnosis of ISM were identified as independent risk factors for HR. For drug-induced HR, prominent risk factors were advSM and high tryptase levels. New reactions were observed in 4.8% of all patients during 4 years follow-up.

CONCLUSIONS:

HR are mainly triggered by Hymenoptera venoms in patients with CM and ISM and by drugs in patients with advSM. Tryptase levels <90 ng/mL, mast cell bone marrow infiltration <15%, and WHO category ISM are predictors of HR. New HR occur in 4.8% of all patients within 4 years.
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Allergy Année: 2024 Type de document: Article Pays d'affiliation: Pologne

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Allergy Année: 2024 Type de document: Article Pays d'affiliation: Pologne